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Abstract Gene therapy employing the suicide gene/prodrug ac-
tivating system Herpes simplex virus type 1 thymidine kinase
(HSV-TK)/ganciclovir (GCV) is e¡ective in killing malignant
tumor cells. Labeling of the HSV-TK enzyme with £uorescent
proteins makes possible the non-invasive imaging of transduc-
tion e⁄ciency, enzyme localization and activity in cell culture
and in animal models of human cancers. Here we report the
expression of HSV-TK tagged with di¡erent £uorescent pro-
teins (EGFP, DSRed1, DsRed2, dsdrFP616) and show that
intracellular localization of the fusion products depends on the
nature of the £uorescent tag despite the presence of several
nuclear targeting signals within the enzyme itself. Coexpression
of red £uorescent HSV-TK fusion proteins with TK-EGFP or
untagged HSV-TK allowed these proteins to enter the nucleus
by inhibiting formation of red £uorescent protein oligomers.
As enzyme localization may in£uence HSV-TK activity, this
observation is of potential importance to gene therapy
studies. 3 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Herpes simplex virus type 1 thymidine kinase (HSV-TK)
phosphorylates naturally occuring nucleosides as well as sev-
eral nucleoside analogs, including ganciclovir (GCV), thereby
converting antiherpetic drugs to cytotoxic metabolites in tu-
mor cells transduced with the HSV-TK gene. Although treat-
ment of malignant brain tumor cells with HSV-TK and GCV
has shown e⁄cacy in cell culture studies and in animal models
of human brain tumors [1^3], clinical trials for treatment of
malignant brain tumors employing the HSV-TK/GCV system
did not result in any treatment bene¢t [4]. The failure of this
therapeutic strategy in humans may be related to the rather
low transduction rate of human tumor cells in vivo. There-
fore, imaging the localization, activity and persistence of
transgenic HSV-TK in living tumor cells may be a ¢rst step
towards optimization of gene therapy protocols.
The HSV-TK gene encodes a protein of 375 amino acids
and contains several nuclear localization signals. Crystallo-
graphic analysis revealed that HSV-TK may form a homo-
dimer [5]. Mutation of the nonapeptide 25RRTALRPRR33
was shown to result in loss of the predominant nuclear local-
ization of HSV-TK [6]. However, the mutated enzyme, de-
tected in both the cytosol and the nucleus, retained kinase
activity. Two additional positively charged sites, R236^R237
and K317^R318, also seem to be important for nuclear traf-
¢cking [7]. Mutation of these sites resulted in predominant
enrichment of the enzyme in the cytosol. K317^R318 are lo-
cated at the interface between the two HSV-TK monomers
and R318 seems to be crucial for formation of the HSV-TK
dimer. It has been proposed that only dimeric HSV-TK is
transported to the nucleus due to a special nuclear localization
signal formed only in the HSV-TK dimer [7].
Recently, reports on non-invasive in vivo imaging of HSV-
TK activity with positron-emission tomography and radiola-
beled nucleoside analogs such as 124I-FIAU (2P-£uoro-2P-de-
oxy-1L-D-arabino-furanosyl-5-iodo-uracil) have been pub-
lished [8,9]. The cloning of genes coding for £uorescent
proteins has introduced new and sensitive reporter molecules
for non-invasive and non-radioactive monitoring of gene ex-
pression. Expression of £uorescent reporters alone or as fu-
sion proteins o¡ers the possibility to monitor in real time
protein expression and localization in single living cells and
in whole organisms. Fluorescent proteins emitting light in the
red spectrum are attractive candidates for multicolor imaging
as their emission maximum is distant from the widely em-
ployed green £uorescent protein (GFP) (Vmax 508 nm) and
light transmission through tissue is higher when using red
shifted probes (s 600 nm) [10].
GFP, isolated ¢rst from the jelly¢sh Aequorea victoria, has
been established as a sensitive and non-invasive reporter sys-
tem for monitoring transgene expression [11,12]. EGFP, a
mutant form of GFP, £uoresces 35-fold more intensely than
the wild type protein [13]. The red £uorescent protein (RFP)
DsRed has been cloned recently from Discosoma coral [14]
and is commercially available as DsRed1 (Clontech, Palo
Alto, CA, USA). The 28 kDa protein DsRed is excited at
558 nm, shows an emission maximum at 583 nm and a sig-
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ni¢cant light emission above 600 nm. While GFP is mono-
meric, shows only a weak propensity to dimerize, and acquires
bright £uorescence relatively fast, DsRed1 forms a tight tet-
ramer (approx. 115 kDa) and shows a slow chromophore
maturation of up to 48 h [15]. Each monomer is structurally
very similar to GFP and displays approximately 24% sequence
homology. Fusion of DsRed to another protein may impair
its function and localization due to formation of tetramers or
even higher-order aggregates of the DsRed moiety [16,17].
Furthermore, a direct toxic e¡ect of DsRed on cells has
been discussed [16,17]. Basic residues near the N-terminus
might lead to formation of salt bridges with adjacent tet-
ramers, thereby promoting aggregation. Recently, Yanushe-
vich et al. introduced mutations of basic residues located
N-terminally in DsRed (R2A, K5E, K9T) resulting in a
low-aggregating form of the protein [18]. The cDNA coding
for this mutagenized protein is available commercially as
DsRed2 (Clontech, Palo Alto, CA, USA). A DsRed variant
whose emission maximum has been further red-shifted by
mutagenesis was described by Fradkov et al. [19] : dsdrFP616
is excited at 583 nm and emits light at Vmax of 616 nm while
showing identical £uorescence yield as DsRed1. DsdrFP616 is
approx. 96% homologous to DsRed2 and has not been muta-
genized N-terminally as described above for DsRed2 (Fig. 1).
Here, we have fused EGFP, DsRed1, DsRed2, and
dsdrFP616 to HSV-TK in order to use these fusion constructs
as reporters for imaging of HSV-TK activity in living glioma
cells, and have investigated the subcellular localization of the
di¡erent fusion proteins.
2. Materials and methods
2.1. Construction of cDNAs
The HSV-TK cDNA was ampli¢ed from the retroviral vector
G1Tk1SvNa [20] by PCR and ligated to the plasmids pDsRed2-N1
or pdsdrFP616-N1 (both Clontech, Palo Alto, CA, USA), respec-
tively. The HSV-TK gene was inserted in frame upstream of the red
£uorescent reporter genes. The 8 amino acid spacer sequence between
full length HSV-TK and both RFPs was identical. Before availability
of DsRed2, a TK-DsRed1 translational fusion had been constructed
by fusing a truncated HSV-TK lacking 6 amino acids at the 3P-end to
full length DsRed1. The intervening sequence consisted of 6 amino
acids. TK-EGFP (kind gift, C.M. Kramm, Dusseldorf, Germany) was
constructed as reported elsewhere [21]. All fusion genes were placed
under the control of the CMV promoter. The correct sequence of the
fusion constructs was con¢rmed by sequencing.
2.2. Cell culture and transfection
The human glioblastoma cell lines U87MG and T98MG, as well as
human embryonic kidney HEK293 cells, murine embryonic NIH3T3
¢broblasts and rat hepatocytes were cultured under standard condi-
tions. For transfection, cells were seeded in 6-well plates at a density
of 3^5U105 cells/well 16^24 h prior to transfection. Cells were trans-
fected under serum-free conditions with Lipofectamine (Invitrogen,
Groningen, The Netherlands) according to the manufacturer’s proto-
col. Fluorescence images were taken 24^48 h after transfection using a
Nikon TS100 inverted microscope equipped with a Coolpix 990 digital
camera (Nikon, Tokyo, Japan). For selection of stable transfectants
transfected cells were replated at low density 48 h after transfection
and incubated with 1 mg/ml f.c. geneticin (Calbiochem, Bad Soden,
Germany) for 4 weeks. Single cell clones were picked and analyzed for
transgene expression.
2.3. Cytotoxicity assay
U87MG or HEK293 cells stably transfected with either HSV-TK or
the respective HSV-TK fusion constructs were seeded at 4^8U103
cells/well in a 96-well plate. GCV was added at ¢nal concentrations
of 0^20 Wg/ml and cells were incubated at 37‡C/5% CO2 for 4 days.
MTT (Sigma, Deisenhofen, Germany) was added at a ¢nal concen-
tration of 0.5 mg/ml for 3 h. Absorbance was measured in a plate
reader (Victor2, Perkin Elmer Life Sciences, Turku, Finland) at
590 nm (reference 660 nm). Experiments were performed in quadru-
plicates.
3. Results and discussion
3.1. Expression of fusion constructs
After transient transfection of human glioblastoma cells,
HEK293 cells, NIH3T3 cells and rat hepatocytes with
DsRed1, DsRed2, dsdrFP616 and EGFP, £uorescence was
visible throughout both the cytoplasm and the nucleus (data
not shown).
In the majority of cells expressing TK-DsRed2 and TK-
dsdrFP616 fusion proteins tightly packed highly £uorescent
aggregates were visible within approximately 30 h after trans-
fection (Fig. 2). Although both fusion proteins contained
identical nuclear targeting sequences in their HSV-TK moiety,
only TK-DsRed2 was located predominantly as uniformly
shaped and strongly £uorescent aggregates in the nucleus
while TK-dsdrFP616 was visible as massive polymorphic ag-
gregates in the cytoplasm with virtually no simultaneous
staining of the nucleus (Fig. 2). The strong tendency of
dsdrFP616 to precipitate from solution has been described
before [19] and most likely accounts for the observed intra-
cellular distribution of TK-dsdrFP616. DsdrFP616 alone
Fig. 1. Alignment of DsRed2, DsRed1, dsdrFP616, and EGFP. Identical residues are represented by dashes, introduced gaps by dots. The
numbering refers to the DsRed2 sequence. Sequences of the commercially available £uorescent proteins (Clontech, Palo Alto, CA, USA) are
used. Note that amino acid valine has been introduced at position 2 into the wild type forms of DsRed1, dsdrFP616, and GFP by the manu-
facturer. Amino acids substituted at the N-terminus in DsRed2 leading to a low-aggregating form of DsRed are shaded.
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Fig. 2. Expression of dsdrFP616- and DsRed2-tagged HSV-TK in di¡erent cell lines. While TK-DsRed2 is transferred to the nucleus, expression of TK-dsdrFP616 results in massive aggregation































tends to aggregate even more than DsRed1, while the N-ter-
minally mutated protein DsRed2 does not. As described
above for DsRed2, Yanushevich et al. [18] introduced the
mutations K5E and K9T into dsdrFP616 and demonstrated
that the mutated protein shows a lower tendency to aggregate.
Introducing additionally the mutations S2del and C3del even
further improved solubility of dsdrFP616. As seen with TK-
dsdrFP616, cells expressing the TK-DsRed1 fusion also £uo-
resced predominantly in the cytoplasm but showed far less
tendency to aggregate as compared with TK-dsdrFP616
(Fig. 3). N-terminally mutated DsRed (DsRed2) seems to fa-
cilitate nuclear transport of DsRed-tagged proteins containing
nuclear localization signals, most likely by reducing the like-
lihood of aggregate formation. It is conceivable that trans-
fection of HSV-TK fused to N-terminally mutated dsdrFP616
will also result in nuclear transfer of this fusion protein. While
£uorescence in cells transfected with the EGFP-TK construct
was homogenous and completely restricted to the nucleus,
cells transfected with TK-EGFP showed predominant homo-
genous labeling of the nucleus as well as staining of the cyto-
plasm, indicating that the precise position of the nuclear tar-
geting sequences within the fusion gene also in£uences protein
localization (Fig. 3). As often seen in transient transfection
experiments [18] aggregates occurred occasionally in brightly
£uorescing cells that had been transfected with EGFP-tagged
HSV-TK, most likely due to protein overexpression (data not
shown). DsRed2-tagged HSV-TK, as well as TK-EGFP and
EGFP-TK can obviously pass through nuclear pores. How-
ever, unlike TK-EGFP, TK-DsRed2 precipitates intranu-
clearly, indicating that the N-terminally introduced mutations
into DsRed2 are not su⁄cient to prevent aggregation after
transport of the fusion proteins into the nucleus.
Fig. 3. Expression of TK-DsRed1, TK-EGFP, and EGFP-TK in HEK293 cells. While TK-DsRed1 aggregates in the cytoplasm and is excluded
from the nucleus, TK-EGFP and EGFP-TK are able to gain access to it. The homogenous intranuclear structures seen in EGFP-TK trans-
fected cells represent nuclear bodies similar to those seen when tagging £uorescent proteins with a nuclear targeting sequence only ([24], and K.
Schlu«ter, Clontech, personal communication).
Fig. 4. Cotransfection of DsRed2-, DsRed1- or dsdrFP616-tagged HSV-TK with TK, EGFP or TK-EGFP into HEK293 cells (molar ratio 1
(RFP-TK):3). The strongest e¡ect on solubility and nuclear transport of RFP-tagged HSV-TK can be seen when cotransfecting TK-EGFP.
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3.2. Rescue of HSV-TK tagged with di¡erent RFPs
We examined whether aggregation could be reduced by
employing the ‘rescue strategy’ described by Lauf et al. [17].
This group had shown that DsRed1-tagged connexins aggre-
gated perinuclearly in opposite to their untagged connexin
counterparts which normally assemble as oligomeric gap junc-
tion channel proteins in plasma membranes. Correct localiza-
tion of the DsRed-tagged proteins could be achieved by co-
transfecting either untagged or EGFP-tagged connexins and
increased with the amount of plasmid added. Cotransfection
of DsRed1-tagged connexins with EGFP alone was not de-
scribed by these authors.
We cotransfected TK-DsRed1, TK-DsRed2, and TK-
dsdrFP616 with EGFP, HSV-TK or TK-EGFP at di¡erent
molar ratios (1:1 and 1:3) into U87MG and HEK293 cells.
Cotransfection of TK-DsRed1 and TK-dsdrFP616 with
EGFP resulted in improved homogenous bright red staining
of the cytoplasm, but nuclear red £uorescence was visible only
occasionally when high doses of EGFP were administered
(Fig. 4). This e¡ect was more pronounced in TK-DsRed1-
than in TK-dsdrFP616-transfected cells. When TK-DsRed2
was cotransfected with EGFP, an increased fraction of cells
contained homogenously red £uorescing nuclei (Fig. 4). Sol-
ubility increased with the amount of EGFP-plasmid added.
Given the virtual identity of the overall fold of GFP and
DsRed and the proposed ability of DsRed-like £uorescent
proteins to hetero-oligomerize [22,23] it seems reasonable to
assume that EGFP can substitute for RFPs in oligomer for-
mation, thereby preventing tetramerization and thus the for-
mation of higher-order aggregates. It would be interesting to
see whether aggregation of DsRed1-tagged connexins as de-
scribed by Lauf et al. [17] could also be prevented at least
partially by EGFP-cotransfection. As connexins oligomerize
also normally into large connexins, the e¡ect of EGFP alone
on solubility of DsRed1-tagged connexins might be less prom-
inent than observed in our system. Nuclear targeting of RFP-
tagged HSV-TK is not enhanced signi¢cantly by EGFP as
EGFP alone does not promote TK-dimerization, which
most likely is a prerequisite for nuclear transfer of the fusion
protein [6,7]. Cotransfection of all three RFP-TK fusion con-
structs with HSV-TK alone had a similar but less pronounced
positive e¡ect on homogenous intracellular distribution of red
£uorescence (Fig. 4), indicating that dimerization of RFP-
tagged HSV-TK might still enable the RFP tag to form olig-
omers or even larger aggregates. On the other hand, HSV-TK
cotransfection at a molar ratio of 1:3 facilitated nuclear trans-
fer of RFP-tagged HSV-TK in cells expressing TK-DsRed1
and TK-dsdrFP616, most likely due to dimerization of HSV-
TK with RFP-tagged HSV-TK (Fig. 4).
The greatest and most impressive positive e¡ect on solubil-
ity and nuclear transfer rate of RFP-tagged HSV-TK could be
achieved by cotransfecting TK-EGFP (Fig. 4). This e¡ect
could be seen in both U87MG glioblastoma and HEK293
cells and increased with the amount of TK-EGFP added.
TK-DsRed2 was now homogenously distributed in the nu-
cleus of virtually all cotransfected cells (Fig. 4). Cotransfec-
tion of TK-DsRed1 or TK-dsdrFP616 with TK-EGFP also
improved their solubility and resulted in greatly enhanced
nuclear transfer of the fusion proteins. Given the strong pro-
pensity of dsdrFP616 to form aggregates [19] cotransfection of
TK-EGFP into TK-dsdrFP616 expressing cells still did not
lead to complete homogenous staining of the cells. The e¡ect
of TK-EGFP on solubility and intracellular distribution of
RFP-tagged HSV-TK seems to combine the positive e¡ects
seen when cotransfecting either HSV-TK or EGFP alone.
While the EGFP moiety increases solubility of all RFP-tagged
proteins the HSV-TK part, which has less impact on RFP
solubility, supports tra⁄cking of the RFP-TK heterodimer
into the nucleus. As large red £uorescent aggregates were
not seen intranuclearly in cotransfected cells, heterodimeriza-
tion seems to prevent cross-linking of RFP-tagged TK into
higher-order aggregates.
DsRed is an obligate tetramer in solution [15], but it is
unknown at present whether oligomerization is a prerequisite
for red £uorescence in living cells. In vitro, DsRed monomers
were shown to £uoresce at 583 nm after disassembly of the
DsRed tetramer by sodium dodecyl sulfate treatment [17]. As
deduced by Lauf et al. [17] from their cotransfection experi-
ments with DsRed-tagged connexin, our data also suggest
that red £uorescence can be emitted by oligomers containing
less than four RFP tags. Remarkably, cells coexpressing RFP-
TK and either HSV-TK, TK-EGFP or EGFP £uoresced more
brightly than cells expressing only RFP-tagged HSV-TK. This
points out the possibility that £uorescence emission is en-
hanced in RFPs consisting of less than four (identical) mole-
cules as a consequence of a dequenching e¡ect.
3.3. Stable expression of transgene proteins
Human glioblastoma cells stably expressing DsRed1,
DsRed2, EGFP and dsdrFP616 could be established by selec-
tion with G418. Establishment of stable glioblastoma cell
clones expressing DsRed1 proved to be di⁄cult, as reported
for other cell lines [18], indicating that this protein is also
toxic for malignant brain tumor cells. We did not succeed in
establishing any stable clones expressing TK-DsRed2 and TK-
dsdrFP616 (TK-DsRed1 was not tested) in several human
glioblastoma cell lines, while TK-EGFP expressing stable
clones could be generated. In HEK293 cells, only one stable
clone expressing TK-DsRed2 but no clones expressing TK-
dsdrFP616 could be established. As expected, HEK293 cells
stably expressing TK-DsRed2 were far less £uorescent than
their transiently transfected counterparts. Unlike transiently
transfected cells, £uorescence in clones stably expressing
Fig. 5. GCV sensitivity of HEK293 and U87MG cells stably ex-
pressing HSV-TK, TK-EGFP or TK-DsRed2, respectively. These
clones as well as control cells were exposed to di¡erent concentra-
tions of the nucleoside analogue GCV for 4 days. Cytotoxicity was
assessed by the MTT assay.
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TK-DsRed2 was distributed more evenly throughout the cy-
toplasm. However, £uorescent aggregates were still seen with-
in these cells. Interestingly, the MTT cytotoxicity assay
showed that these cells retained HSV-TK activity and were
killed by GCV (Fig. 5). Human U87MG glioblastoma cells
stably expressing HSV-TK and TK-EGFP were also shown to
be sensitive to GCV, thus con¢rming that expression of the
tagged or untagged wild type HSV-TK protein resulted in a
functionally active enzyme in human glioblastoma cells (Fig.
5). The reduced sensitivity of HSV-TK expressing HEK293
cells towards GCV compared with HSV-TK expressing
U87MG glioma cells can be ascribed most likely to di¡erences
in cell-speci¢c properties, as this phenomenon is observed with
cell clones expressing either tagged or untagged HSV-TK (Fig.
5).
In conclusion, fusion of HSV-TK to RFPs o¡ers a valuable
tool to study transgene expression in human malignant brain
tumors. However, the success of this approach requires that
oligomerization and aggregation of the RFP moiety is avoided
by either using mutated RFPs which have lost the tendency to
aggregate or by coexpression of other proteins which limits
tetramerization and aggregation of red £uorescent HSV-TK
fusion proteins.
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